AI assistant
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2025
Apr 10, 2025
33148_dirs_2025-04-10_fd7e531f-bf44-4205-ab60-accece686def.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2025-04-09
Reporting Person: Patel Kinnari (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-04-09 | Common Stock | P | 21099 | $4.7 | Acquired | 26774 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 444103 | Direct |
| Common Stock | 104927 | Indirect |
Footnotes
F1: On April 9, 2025, the Reporting Person's husband purchased 21,099 shares of Common Stock in a series of brokered transactions at prices ranging from $4.65 to $4.78 and a weighted average price per share of $4.70 (rounded to two decimal places), for an aggregate purchase price of approximately $99,157. The detailed breakdown of executed sales will be furnished upon request.
F2: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F3: The shares are held indirectly through Adaptive Technology, LLC, a limited liability company that is owned and managed by the reporting person's husband.